Orion Oyj stock (FI0009014377): US FDA approves animal health drug

Orion Animal Health secured US FDA approval for Tessie, a tasipimidine oral solution treating noise aversion and separation anxiety in dogs. The Finnish pharma firm's US market expansion bolsters its veterinary portfolio.

Orion Oyj's animal health division received US FDA approval for Tessie (tasipimidine oral solution), targeting noise aversion and separation anxiety in dogs, according to PharmaBiz as of recent and MarketScreener. This regulatory milestone enhances Orion's veterinary offerings amid growing US pet care demand.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Orion Oyj
• Sector/industry: Pharmaceuticals
• Headquarters/country: Finland
• Core markets: Europe, US
• Key revenue drivers: Human and veterinary drugs
• Home exchange/listing venue: Nasdaq Helsinki (ORNBV)
• Trading currency: EUR

Orion Oyj: core business model

Orion Oyj develops, manufactures, and markets human pharmaceuticals, veterinary medicines, and active pharmaceutical ingredients. Headquartered in Espoo, Finland, the company focuses on proprietary research and in-licensing, with a strong emphasis on neurology, oncology, and animal health. Its B shares trade on Nasdaq Helsinki under ORNBV.

The firm reported a 23.13% stock rise over the past year as of data published on Investing.com, reflecting resilience in volatile markets. Orion's integrated model spans from R&D to global commercialization, serving key markets in Europe and increasingly the US.

Main revenue and product drivers for Orion Oyj

Human pharmaceuticals account for the bulk of revenue, driven by products like Easyhaler inhalers and CNS treatments. Veterinary sales, including animal health innovations like Tessie, contribute significantly. The US FDA nod positions Tessie to tap into the expanding $1.5 billion US pet anxiety market.

Orion's shares traded around 57-60 EUR recently on Nasdaq Helsinki, with a 52-week range of 54.15-75.30 EUR per Investing.com historical data. Growth stems from pipeline advancements and partnerships.

Industry trends and competitive position

The global veterinary pharmaceuticals market grows at 7% annually, fueled by pet humanization trends in the US. Orion competes with Zoetis and Elanco but differentiates via innovative solutions like tasipimidine, a novel alpha-2 adrenoceptor agonist for canine anxiety.

This approval underscores Orion's regulatory expertise, vital for US investors eyeing European pharma with transatlantic exposure.

Why Orion Oyj matters for US investors

Listed on Nasdaq Helsinki, Orion offers US investors access to a stable Finnish blue-chip with US FDA-validated products. Its animal health push aligns with America's 70 million dog-owning households, providing diversification beyond domestic biotech volatility.

Conclusion

The US FDA approval for Tessie marks a key step for Orion Oyj's animal health expansion into the lucrative US pet market. With a solid business model and recent stock performance, the company maintains relevance for global investors. Market dynamics and pipeline progress will shape future developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.